68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
This phase II trial studies the impact of 68GA-PSMA-11 positron emission tomography
 (PET)/computed tomography (CT) scan on treatment strategies for patients with prostate
 cancer. Diagnostic imaging procedures, such as 68GA-PSMA-11 PET/CT scan, may help doctors
 plan the best treatment for prostate cancer.
PRIMARY OBJECTIVES:

 I. To determine the impact of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) PET/CT on initial
 and subsequent treatment strategies of patients with prostate cancer.

 OUTLINE:

 Patients receive 68Ga-PSMA-11 intravenously (IV) and undergo PET/CT scan over 3 hours.
 Patients may be reenrolled in the study, if 68Ga-PSMA-11 PET/CT is performed for subsequent
 management decision.

 After completion of study, patients are followed up within 3-12 months.
Inclusion Criteria:

 -  Patients who fulfill criteria for initial staging or restaging as outlined below:

 -  Initial treatment strategy decisions (initial staging): All patients with
 histologically proven prostate cancer or strong suspicion of prostate
 adenocarcinoma based on very high prostate-specific antigen (PSA) levels (> 50
 ng/mL) who require an initial treatment/management decision who may be candidate
 for any of the following strategies:

 -  Surgery

 -  External radiation therapy (RT)

 -  Other focal therapies

 -  Systemic medical treatment

 -  Watchful waiting

 -  Assessment for subsequent treatment strategy (restaging), any of the following:

 -  Patients with biochemical recurrence who are potential candidates for any
 salvage treatment. Biochemical recurrence is defined by rising PSA after
 definitive therapy with prostatectomy or radiation therapy, as any of the
 following:

 -  Post radical prostatectomy (RP): PSA equals to or greater than 0.2
 ng/mL measured more than 6 weeks after RP

 -  Post-radiation therapy: Nadir + greater than or equal to 2 ng/mL rise
 in PSA

 -  Patients with known prostate cancer who undergo restaging because of new
 symptoms

 -  Patients with known metastatic prostate cancer who undergo restaging because
 of rising PSA with negative or inconclusive conventional imaging

 -  Patients with known prostate cancer who are treated medically or with
 radioligand therapy (RLT) in whom response to treatment is assessed

 -  Note: Patients may be reenrolled in the study, if 68Ga-PSMA PET/CT is
 performed for subsequent management decision

 -  Capability to provide written informed consent

 -  Able to remain still for duration of each imaging procedure (about 30 minutes)

 Exclusion Criteria:

 -  Inability to complete the needed investigational and standard-of-care imaging
 examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

 -  Any additional medical condition, serious concurrent illness, or other extenuating
 circumstance that, in the opinion of the Investigator, may significantly interfere
 with study compliance

 -  Inability to provide written informed consent